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ABSTRACT:  21 
Ubiquinone (UQ) is a polyprenylated lipid that is conserved from bacteria to humans and is 22 
crucial to cellular respiration. How the cell orchestrates the efficient synthesis of UQ, which involves 23 
the modification of extremely hydrophobic substrates by multiple sequential enzymes, remains an 24 
unresolved issue. Here, we demonstrate that seven Ubi proteins form the Ubi complex, a stable 25 
metabolon that catalyzes the last six reactions of the UQ biosynthetic pathway in Escherichia coli. The 26 
SCP2 domain of UbiJ forms an extended hydrophobic cavity that binds UQ intermediates inside the 1 27 
MDa Ubi complex. We purify the Ubi complex from cytoplasmic extracts and demonstrate that UQ 28 
biosynthesis occurs in this fraction, challenging the current thinking of a membrane-associated 29 
biosynthetic process. Collectively, our results document a rare case of stable metabolon and highlight 30 
how the supramolecular organization of soluble enzymes allows the modification of hydrophobic 31 
substrates in a hydrophilic environment.  32 
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INTRODUCTION:  33 
Isoprenoid quinones are widespread in the three domains of life and represent a peculiar 34 
group of lipids able to undergo a two-step reversible redox process (Nowicka and Kruk, 2010). The 35 
electron transfer properties of isoprenoid quinones are essential to the function of respiratory chains 36 
that generate cellular ATP (Schoepp-Cothenet et al., 2013). Isoprenoid quinones also mediate disulfide 37 
bond formation in proteins (Bader et al., 2000), participate to virulence and antibiotic resistance in 38 
bacteria (Aussel et al., 2014b) and function as membrane soluble antioxidants (Bentinger et al., 2010; 39 
Nowicka and Kruk, 2010). The main isoprenoid quinones are menaquinone (MK) and ubiquinone (UQ), 40 
which is also called coenzyme Q in eukaryotes. MK and UQ share the same polyisoprenoid tail but 41 
differ by the structure of the redox-active head group, naphthalene ring and benzene ring, respectively 42 
(Figure S1A). The polyisoprenoid tail varies in length between organisms (UQ6 in Saccharomyces 43 
cerevisiae, UQ8 in Escherichia coli and UQ10 in humans) and confers extremely hydrophobic properties 44 
to isoprenoid quinones, which localize consequently in cellular membranes (Kawamukai, 2018; 45 
Nowicka and Kruk, 2010).  46 
In the UQ biosynthesis pathway, the polyisoprenoid tail is added at an early step by an integral 47 
membrane polyprenyltransferase called UbiA in E. coli (Figure 1A). Subsequently, seven consecutive 48 
chemical reactions modify the head group to yield UQ (Figure 1A). Hydrophobic polyprenylated 49 
intermediates of the UQ biosynthetic pathway are predicted to be embedded within the lipid bilayer 50 
(Stefely and Pagliarini, 2017), with the head groups near the glycerol backbone of the membrane 51 
phospholipids and the isoprenoid tail inserted between their acyl chains (Galassi and Arantes, 2015; 52 
Hoyo et al., 2017; Wollstein et al., 2015). In contrast, the decarboxylase, methyltransferases and 53 
hydroxylases of the UQ biosynthetic pathway contain no transmembrane domains and are predicted 54 
to be soluble. Thus, how UQ biosynthetic enzymes overcome the biophysical barrier that separates 55 
them from their lipophilic substrates constitutes an unresolved issue. 56 
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Besides the Ubi enzymes that catalyze the chemical reactions of the pathway (Figure 1A), three 57 
Ubi proteins of unknown function are also required for efficient UQ biosynthesis, UbiB (Poon et al., 58 
2000), UbiJ (Aussel et al., 2014a) and UbiK (Loiseau et al., 2017). Lately, we demonstrated that purified 59 
UbiJ and UbiK form a 1:2 heterocomplex that binds palmitoleic acid, one of E. coli most abundant fatty 60 
acid (Loiseau et al., 2017). This capacity to bind lipids suggested that UbiJ and UbiK may act as accessory 61 
factors of Ubi enzymes, but the role of these two proteins and of UbiB, although central for UQ 62 
biosynthesis, is still undefined (Bayly and Yadav, 2017; Loiseau et al., 2017; Reidenbach et al., 2017).  63 
Together, UQ biosynthesis raises generic questions about how enzymes deal with extremely 64 
hydrophobic substrates and how cells orchestrate multi-step biosynthetic pathways. In order to 65 
address these fundamental questions, we have studied the subcellular localization and the structural 66 
organization of the UQ pathway in the bacterium E. coli. Here, we show that five Ubi enzymes and the 67 
accessory factors UbiJ-UbiK form a 1000 kDa Ubi complex that resides in the cytosolic fraction. We 68 
demonstrate that UbiJ binds hydrophobic UQ biosynthetic intermediates and is also the keystone of 69 
the Ubi complex. Our work describes the Ubi complex as a unique microreactor, which enables the 70 
multistep biosynthesis of a complex lipid in a hydrophilic cellular environment.  71 
 72 
RESULTS:  73 
UQ biosynthesis takes place in the soluble fraction of E. coli lysates 74 
An assay to monitor UQ biosynthesis in vitro is not available (Stefely and Pagliarini, 2017). We 75 
designed an in vivo experimental approach to accumulate a labelled version of OPP within cells and to 76 
monitor its conversion into labelled UQ. We transferred ubiC cells pretreated with chloramphenicol 77 
in an O2-free atmosphere and added the labelled precursor 13C7-4HB. The absence of dioxygen blocked 78 
UQ biosynthesis (Shestopalov et al., 1997), and the cells quickly accumulated 13C6-OPP (Figure S1B). 79 
Upon exposure to air, cells preloaded anaerobically with 13C6-OPP synthesized 13C6-UQ8 (Figure S1C). 80 
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Conversely, we observed no 13C6-UQ8 synthesis in cells maintained under argon atmosphere (Figure 81 
S1C). Thus, dioxygen triggered the in vivo conversion of 13C6-OPP into 13C6-UQ8 in our experimental set-82 
up, in agreement with the hydroxylases UbiF, H and UbiI requiring O2 as a cosubstrate (Alexander and 83 
Young, 1978; Hajj Chehade et al., 2013) (Figure 1A). 84 
 Next, we lysed cells loaded with 13C6-OPP and found that total cell free extracts incubated 85 
under air at 30°C also synthesized 13C6-UQ8 (Figure S1D). The biosynthesis of UQ8 was strongly 86 
stimulated by the addition of S-adenosylmethionine and NADH (Figure S1D), which act respectively as 87 
the methyl-donor for the methylation reactions and as the electron-donor for the hydroxylases (Knoell, 88 
1979b). Finally, we fractionated the cell free extracts by ultracentrifugation and assayed the 89 
cytoplasmic and membrane fractions for UQ biosynthesis. Only the cytoplasmic fraction produced 13C6-90 
UQ8 upon exposure to air (Figure 1B and S1E). The initial rates were comparable between the soluble 91 
fraction and cell free extracts (Figure 1B). However increased 13C6-UQ8 synthesis was observed at later 92 
stages in cell free extracts (Figure 1B), potentially reflecting limiting amounts of the 13C6-OPP substrate 93 
in the soluble fraction. In conclusion, we developed an activity assay, which strongly supports that the 94 
last six reactions of the UQ biosynthetic pathway take place in the cytosol.   95 
Ubi proteins are found predominantly in the soluble fraction of E. coli lysates 96 
The presence of UQ biosynthesis activity in the cytoplasmic fraction prompted us to evaluate 97 
the distribution of Ubi proteins. We created several Ubi-SPA strains by inserting a sequence coding for 98 
the SPA tag at the 3’ end of ubi genes in the E. coli chromosome (Figure S1F). The tagged proteins were 99 
functional since the UQ8 content of the strains accounted for at least 70% of WT level (Figure S1G). 100 
Western blot analysis of cellular extracts with an anti-Flag antibody detected the Ubi proteins at their 101 
expected size, except the membrane-bound UbiA and UbiB that did not show any signal (data not 102 
shown). Ultracentrifugation of cell free extracts separated soluble and membrane fractions as verified 103 
by immunodetection of the cytosolic glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and the 104 
membrane-bound porin LamB (Figure 1C). All tested Ubi-SPA proteins distributed in both fractions 105 
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(Figure 1C). We calculated the total amount of each Ubi protein in the entire soluble and membrane 106 
fractions. The ratio of these amounts indicate the distribution of each Ubi protein (Figure 1C) and 107 
showed that all Ubi proteins localized predominantly in the soluble fraction, except UbiK. 108 
Seven Ubi proteins form a 1 MDa complex 109 
To further characterize the soluble Ubi proteins, we analyzed cytoplasmic fractions by Blue 110 
Native PAGE (BN-PAGE), a technique that preserves the integrity of protein complexes and separates 111 
them according to their hydrodynamic size and shape (Wittig et al., 2006). Anti-Flag immunodetection 112 
showed that seven Ubi-SPA proteins (UbiE, F, G, H, I, J, K) co-migrated at 1000 kDa, whereas UbiD and 113 
UbiX co-migrated at around 700 kDa (Figure 2A). Similar results were obtained with an anti-CBP 114 
antibody, demonstrating the specific detection of the SPA tag fused to the Ubi proteins (Figure S2A). 115 
As expected, the tetrameric GAPDH protein (4x35.5 kDa) ran at 140 kDa (Figure 2A and S2A). We also 116 
subjected the samples to a denaturating second dimension electrophoresis (2D SDS-PAGE) after the 117 
first dimension BN-PAGE (1D BN-PAGE). 2D SDS-PAGE confirmed the migration of UbiE, F, G, H, I, J, K 118 
proteins at 1000 kDa and of UbiX and UbiD at 700 kDa (Figure 2B). GAPDH was detected at 100 119 
kDa with variations between experiments due to migration artefacts in the lower part of the gel and 120 
to disparities in the positioning of the 1D BN-PAGE lane (Figure S2B).  121 
To corroborate the co-migration of several Ubi proteins, we used a second method that 122 
separates proteins in glycerol gradients according to their density. UbiE, F, G, H, I, J, K distributed 123 
around the high density fractions 11 to 16, whereas UbiD and X were most abundant in fractions 9 to 124 
13, and GAPDH eluted in fractions 6 to 10 (Figure 2C). Silver staining revealed that most proteins of 125 
the soluble extracts localized in low-density fractions (Figure 2C). We analyzed by 2D SDS-PAGE 126 
fractions 11, 12 and 13 from the glycerol gradient of UbiG-SPA and obtained a signal for the UbiG 127 
protein at 1000 kDa (Figure 2D). Thus, both BN-PAGE and glycerol gradient experiments consistently 128 
established the existence of the same protein complex that we name “Ubi complex”.  129 
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 To provide additional proof of the existence of the Ubi complex, we performed bacterial two-130 
hydrid experiments, in which adenylate cyclase (AC) activity reports on the interaction between Ubi 131 
proteins fused either to the T18 or T25 domains of AC (Karimova et al., 1998). We tested all 132 
combinations (Table S1) and obtained an interaction network where the seven proteins of the Ubi 133 
complex exhibited multiple robust interactions, whereas the other Ubi proteins were less connected 134 
(Figure 2E). Collectively, our results are consistent with UbiE, F, G, H, I, J, K being part of a cytoplasmic 135 
1 MDa Ubi complex, whereas UbiX and UbiD involved in the decarboxylation step form a separate 136 
entity. 137 
Purification of the Ubi complex and identification of its components  138 
Next, we isolated the Ubi complex using sequential affinity purification, a two-step procedure 139 
that uses first the FLAG epitopes of the SPA tag and second its CBP domain (Babu et al., 2009). We 140 
processed soluble extracts from UbiE-SPA cells and from WT untagged cells as control. Both eluates 141 
from the anti-FLAG resin were similar (Figure S2C-D) but immunodetection confirmed the presence of 142 
UbiE-CBP in the UbiE-SPA sample (Figure S2E). E2-E4 eluates of the calmodulin resin showed multiple 143 
bands that were absent in the control eluate (Figure S2F-G) and contained the bait UbiE-CBP protein 144 
as revealed by western blot analysis (Figure S2H). We detected the purified Ubi complex at 1000 kDa 145 
in a 2D SDS-PAGE analysis of the E2 eluate (Figure 3A), with a signal similar to the Ubi complex in total 146 
soluble fractions (Figure 2B).  We similarly purified the Ubi complex from UbiI-SPA and UbiG-SPA strains 147 
and obtained E2 fractions whose SDS-PAGE shared protein bands with the UbiE-SPA fraction E2 (Figure 148 
3B). To identify the proteins in the Ubi complex, all three samples were submitted to mass 149 
spectrometry (MS)-based proteomic analysis and compared with E2 fractions from independent 150 
control purifications. The stringent comparison of MS-based results obtained for SPA-tagged proteins 151 
and negative controls identified several proteins that co-purified with the bait proteins (Table S2). 152 
Interestingly we detected only seven Ubi proteins and all of them were found in a subset of 8 proteins 153 
systematically enriched in the three Ubi-SPA eluates (Figure 3C, Table S2). The 8 proteins were UbiE, 154 
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F, G, H, I, J, K and the lipoprotein Blc, which physiological function remains uncertain (Campanacci et 155 
al., 2006). The UQ8 content of the blc strain was comparable to WT (Figure S2I), showing that the Blc 156 
protein is not required for UQ biosynthesis, unlike Ubi proteins of the Ubi complex. Overall, we 157 
conclude that the biosynthesis of UQ in the soluble fraction (Figure 1B) is mediated by the Ubi complex, 158 
which contains the five enzymes (UbiE, F, G, H, I) necessary to convert OPP to UQ8 (Figure 1A) and two 159 
accessory factors, UbiJ and UbiK.   160 
UQ biosynthetic intermediates OPP and DMQ8 co-elute with the Ubi complex 161 
 Using HPLC coupled to electrochemical detection and mass spectrometry (HPLC-ECD-MS), we 162 
analyzed the distribution of isoprenoid quinones in exponentially growing E. coli cells and found that 163 
the UQ intermediates OPP and DMQ8 accumulated substantially in the cytosolic fraction, whereas UQ8 164 
was highly enriched in the membrane fraction (Figure 4A). Analysis of the cytosols of Ubi-SPA strains 165 
on glycerol gradients revealed that OPP and DMQ8 were enriched in fractions that contain the Ubi 166 
complex, as visualized by western-blot analysis (Figure 4B and S3A-B). Conversely, UQ8 distributed 167 
quite evenly in the gradient (Figure 4B and S3A-B). Together, these results showed that the 168 
hydrophobic intermediates OPP and DMQ8 localized to a significant extent in the soluble fraction of E. 169 
coli extracts and co-eluted with the Ubi complex.  170 
The SCP2 domain of UbiJ binds isoprenoid lipids  171 
We recently showed that the purified UbiJ-UbiK heterocomplex binds palmitoleic acid (Loiseau 172 
et al., 2017), one of the most abundant fatty acid in E. coli. Overexpression of UbiJ-K caused a decrease 173 
in cellular UQ8 levels and the accumulation of OPP and DMQ8 (Figure 4C and S3C), suggesting the 174 
sequestration of these UQ8 biosynthetic intermediates by UbiJ-K.  We then purified the UbiJ-K complex 175 
(Figure S3D) using affinity chromatography and size-exclusion chromatography, and analyzed its 176 
quinone content by HPLC-ECD-MS (Figure S3E). We detected UQ8, OPP and DMQ8 (Figure 4D), showing 177 
that UbiJ-K is able to bind all three isoprenoid lipids.  To elucidate which of the two proteins is 178 
responsible for lipid binding, we purified UbiK and the N-terminal SCP2 domain of UbiJ (UbiJ-SCP2) 179 
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(Figure S5E); full-length UbiJ was not amenable to purification. We detected UQ8, OPP and DMQ8 in 180 
UbiJ-SCP2, but not in UbiK samples (Figure 4D and S3E). The calculated UQ8 /protein ratio showed a 181 
low occupancy in UbiJ-K and UbiJ-SCP2 (less than 0.3 %), probably due to the high yield expression and 182 
the multiple purification steps. Together, our results strongly support that the SCP2 domain of UbiJ, 183 
and not UbiK, is responsible for binding UQ8 and the biosynthetic intermediates OPP and DMQ8 in the 184 
Ubi complex.  185 
Structure of the SCP2 domain of UbiJ 186 
UbiJ-SCP2 behaved as a dimer in solution and crystallized in the space group P212121 with an 187 
asymmetric unit containing either a dimer or a tetramer (Table S3). The structure shown in Figure 5A 188 
is that of the dimer generated with data collected to the highest 1.7 Å resolution. An electron density 189 
map is shown in Figure S4. The protein has an /-fold with 5 -helices and 5 -strands forming a 190 
hydrophobic center with an open cavity (Figure 5B). The walls of this cavity are composed of 191 
hydrophobic residues provided both by the -helices and the -strands (Figure 5C-D). It is interesting 192 
to note that, at those specific positions, UbiJ-SCP2 domains have exclusively hydrophobic residues 193 
(Figure S5). The overall structure, as well as the presence of a hydrophobic cavity, is highly reminiscent 194 
of previously reported structures of the SCP2 protein family (Table S4). This suggests that the absence 195 
of the C-terminal part of UbiJ does not perturb the SCP2 domain in line with our model showing two 196 
independent domains (Loiseau et al., 2017). In some cases, SCP2 proteins have been crystallized in 197 
complex with a hydrophobic ligand as a further evidence for the cavity playing a functional role in lipid 198 
binding (Table S4) (Burgardt et al., 2017; De Berti et al., 2013; Dyer et al., 2008; Haapalainen et al., 199 
2001). Although the model we present does not contain any ligand, electron density was noted within 200 
the cavity (Figure 5C). It is tempting to suggest that this unexplained density is related to the various 201 
lipids detected in small quantities within the purified protein (see above) and that the cavity of UbiJ 202 
serves as the binding site for UQ8 intermediates. As a final support to that hypothesis we found that a 203 
UQ8 conformation taken from a previously reported structure of photosynthetic LH1-RC protein in 204 
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complex with UQ8 (Yu et al., 2018) nicely aligns into this cavity, with a reasonable fit in length (Figure 205 
5E).  206 
 207 
UbiJ is essential to the stability of the Ubi complex 208 
Our characterization of UbiJ as a polyprenyl lipid-binding protein led us to characterize OPP 209 
binding to the Ubi complex in ubiJ cells. ubiJ cells are blocked at an undefined early step of the UQ 210 
biosynthetic pathway (Aussel et al., 2014a) and have therefore a strongly diminished UQ8 content and 211 
increased OPP levels compared to WT cells (Figure S6A). The cytosol of UbiG-SPA ubiJ cells analyzed 212 
on glycerol gradient showed a profile with comparable amounts of OPP and UQ8 in all fractions (Figure 213 
6a). A similar result was obtained with UbiF-SPA ubiJ and UbiH-SPA ubiJ cells (Figure S6B-C). This 214 
distribution of OPP is in stark contrast with the accumulation of OPP in the Ubi complex observed in 215 
cells that contain UbiJ (Figure 4B and S3A-B).  216 
The deletion of ubiJ did not affect the steady state level of UbiF or UbiG but lowered that of 217 
UbiH (Figure S6B). Western-blot analyses revealed that the Ubi proteins shifted from fractions 11-16 218 
(Figure 2c) in WT cells to fractions 2-10 in ubiJ cells (Figure 6A and S6C-D), whereas the position of 219 
GAPDH was unchanged (compare Figure 6A and 2C). BN-PAGE and 2D-SDS-PAGE analyses showed that 220 
the Ubi complex was absent in ubiJ cells (Figure 6B-D). Conversely, the Ubi complex was readily 221 
detected in cells lacking ubiE, ubiF, ubiG (Figure 6B-C) or ubiK (Figure 6E), even though deletion of this 222 
last gene decreased UbiI levels (Figure S6E). Interestingly, cells with a Ubi complex lacking an enzymatic 223 
subunit like UbiF or UbiE produced substantial quantities of the late stage intermediates DMQ8 and 224 
DDMQ8, respectively (Figure S6F). Together, our results show that UbiJ is required for the stability of 225 
the Ubi complex and explain why UQ biosynthesis cannot progress past the early intermediate OPP in 226 
ubiJ cells.   227 
 228 
11 
 
DISCUSSION:  229 
Here, we demonstrate the supramolecular organization of seven UQ biosynthesis proteins in 230 
a 1 MDa Ubi complex (Figure 2), which is remarkable for at least 2 reasons. First, it constitutes a stable 231 
metabolon, a term that designates the association of sequential enzymes acting in a metabolic 232 
pathway (Srere, 1985). Often, metabolons are highly dynamic and therefore not amenable to 233 
biochemical characterization (Laursen et al., 2016; Nguyen et al., 2014; Wu and Minteer, 2015), like 234 
the purinosome. However, a few stable metabolons have been purified like the pyruvate 235 
dehydrogenase complex (Zhou et al., 2001) or a triacylglycerol biosynthetic complex in Rhodotorula 236 
glutinis (Gangar et al., 2001). We have shown that the Ubi complex contains two accessory factors 237 
(UbiJ, K) and the Ubi enzymes (UbiI, G, H, E, F) that catalyze the last six reactions of the UQ biosynthesis 238 
pathway. As such, the Ubi complex is, to our knowledge, the first example of athe stable metabolon 239 
that coordinating coordinates the  so manyhighest number of chemical reactions. Substrate channeling 240 
between Ubi enzymes and control of undesired reactivity of UQ intermediates may be conferred by 241 
the Ubi metabolon to contribute to efficient UQ biosynthesis.   242 
Second, the Ubi complex is present in the cytosolic fraction even though its polyprenylated 243 
substrates count among the most hydrophobic molecules in life (Nowicka and Kruk, 2010; Stefely and 244 
Pagliarini, 2017). As a matter of fact, we have experimentally established that the biosynthetic steps 245 
from OPP to UQ8 proceed in the cytosolic fraction, independently from the membrane, as suggested 246 
by an early report (Knoell, 1979a) and supported by the following results: i) OPP and DMQ8, two UQ8 247 
biosynthetic intermediates, accumulated in the cytosolic fraction to a greater extent than the mature 248 
UQ8 and co-purified with the soluble Ubi complex (Figure 4), ii) the Ubi metabolon was located in the 249 
soluble fraction, which actively converted OPP into UQ8 in vitro, unlike the membrane fraction (Figure 250 
1B). We believe that UbiJ is key to create, in the Ubi complex, a microenvironment that isolates 251 
lipophilic molecules from the surrounding hydrophilic cytoplasm. Indeed, we demonstrated that the 252 
SCP2 domain of UbiJ binds UQ biosynthetic intermediates (Figure 4) and the crystal structure revealed 253 
12 
 
an elongated hydrophobic cavity, which size and shape is compatible with the binding of the polyprenyl 254 
tail of UQ intermediates (Figure 5). SCP2 domains are typically found lone (unfused) or in multidomain 255 
proteins and fulfill lipid-binding and transport functions in all domains of life (Burgardt et al., 2017).  256 
We demonstrated here for the first time the presence of a SCP2 protein in a multiprotein complex 257 
involved in lipid modification. Altogether, we propose a model of UQ8 biosynthesis, in which the 258 
hydrophobic UQ intermediates downstream of OPP are not associated to membrane lipids but to UbiJ 259 
within the soluble Ubi metabolon (Figure 6F). 260 
Since the early prenylation step by UbiA takes place in the membrane (Cheng and Li, 2014; 261 
Huang et al., 2014), our model postulates that the early octaprenyl intermediates (either OHB or OPP) 262 
move out of the membrane so that OPP can bind to UbiJ in the soluble Ubi complex. This mechanism 263 
is unusual because enzymes that synthesize lipids are often membrane-bound or membrane-264 
associated, like the phospholipid biosynthetic pathways in E. coli (Lopez-Lara and Geiger, 2017).  265 
However, the extrusion of a lipid from the membrane to allow its chemical modification has a 266 
precedent, with the eukaryotic Sec14 that extracts phosphatidylinositol from the membrane and 267 
presents it to soluble hydroxylases (Bankaitis et al., 2010). In the case of UQ biosynthesis, we believe 268 
that the accessory factor UbiB may assist the extrusion of either OHB or OPP from the membrane 269 
(Figure 6F). Indeed, UbiB and its eukaryote homolog Coq8 were recently hypothesized to couple the 270 
hydrolysis of ATP to the extraction of head groups of UQ intermediates out of the membrane 271 
(Reidenbach et al., 2017; Stefely et al., 2016). Of note, UbiB contains one transmembrane domain and 272 
is not part of the purified Ubi complex (Table S2), consistent with the soluble nature of the latter. 273 
Reciprocally, how UQ8 is delivered to the membrane bilayer after its synthesis by the soluble Ubi 274 
complex will be addressed in future studies. Overall, UbiK may also play a role in trafficking  the 275 
polyprenyl molecules in and out of the membrane as a significant part of UbiK associates with the 276 
membrane (Figure 1C) and it was described to enhance the fusion of membranes in vitro (Carrica et 277 
al., 2011). 278 
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UbiJ and UbiK are conserved in many proteobacteria (Loiseau et al., 2017; Xia et al., 2017) and 279 
we demonstrated that both proteins are bona fide subunits of the Ubi complex. Besides binding UQ 280 
intermediates, we also found that UbiJ was an essential structural element of the Ubi complex, unlike 281 
other Ubi proteins (Figure 6B-E). We showed previously that the C-terminal domain of UbiJ was 282 
essential for UQ biosynthesis in vivo and formed an extended α-helix that likely associated within a 283 
three-helix bundle in the UbiK2-UbiJ1 heterocomplex (Aussel et al., 2014a; Loiseau et al., 2017). Taking 284 
all these findings into account, we propose that UbiJ is the keystone of the Ubi complex and constitutes 285 
a docking platform where Ubi enzymes assemble and access their SCP2-bound polyprenyl substrates. 286 
The total molecular weight of the eight proteins identified in the purified Ubi complex approaches 270 287 
kDa, still far from the estimated 1 MDa observed on BN-PAGE. The extra mass may correspond to 288 
multimeres of Ubi proteins in the Ubi complex, as supported by a study that found members of 289 
multiprotein complexes to be made in precise proportion to their stoichiometry, and showed that Ubi 290 
proteins have heterogeneous synthesis rates (Li et al., 2014). We also found that several Ubi proteins 291 
interacted with themselves in our two-hybrid assay (Table S1), supporting that they may multimerize.  292 
Based on the conservation of Ubi proteins, it is tempting to suggest that the UQ biosynthetic 293 
pathway of many proteobacteria is organized around a soluble stable metabolon, like in E. coli. 294 
Nonetheless, we expect different versions of the Ubi complex across proteobacteria because of 295 
variations in the number of UQ hydroxylases (Pelosi et al., 2016) and of other components of the 296 
pathway (Esposti, 2017). In eukaryotes, it is unclear whether a UQ biosynthesis metabolon exists since 297 
enzymes are still missing for two chemical reactions of the pathway (Awad et al., 2018). BN-PAGE 298 
experiments showed that several UQ biosynthetic proteins form a complex associated with the 299 
mitochondrial inner membrane in the yeast S. cerevisiae (He et al., 2014; Marbois et al., 2009), and 300 
such supramolecular organization may also exist in mammalian cells (Floyd et al., 2016; Stefely et al., 301 
2016). However, the composition of the complex is uncertain since multiple proteins not related to UQ 302 
biosynthesis co-purified with yeast UQ biosynthetic proteins (Allan et al., 2015). Interestingly, two UQ 303 
biosynthesis proteins of unknown function and restricted to eukaryotes, Coq4 and Coq9, are able to 304 
14 
 
bind lipids (Lohman et al., 2014; Rea et al., 2010) and exhibit genetic interactions with other Coq 305 
proteins (Hsieh et al., 2007; Marbois et al., 2009; Ozeir et al., 2015). We suspect that Coq4 and Coq9 306 
may chaperone UQ intermediates, similar to bacterial UbiJ.  307 
In conclusion, we discovered a stable metabolon - the Ubi complex - that catalyzes UQ 308 
biosynthesis, thanks to the association of five enzymes and two accessory factors. Surprisingly this 309 
metabolon localizes in the cytosolic fraction of E. coli, despite the extreme hydrophobicity of UQ 310 
biosynthetic intermediates. Our work shows that the SCP2 protein UbiJ binds these compounds and 311 
opens new questions regarding the trafficking of polyprenyl lipids in and out of membranes. The Ubi 312 
complex microreactor represents also a fascinating model to study how substrates are sequentially 313 
processed by multiple active sites located in a single structural entity. 314 
 315 
SIGNIFICANCE 316 
Ubiquinone is a conserved isoprenoid lipid of crucial physiological importance. Isoprenoid 317 
intermediates in ubiquinone biosynthesis are extremely hydrophobic; thus the pathway is proposed 318 
to be membrane-associated. Unexpectedly, we demonstrate that most steps in bacterial UQ 319 
biosynthesis are independent of the membrane and occur inside a soluble multiprotein complex that 320 
forms a stable metabolon. We elucidate a key role for the SCP2 domain of the UbiJ protein in binding 321 
the isoprenoid intermediates inside the multiprotein complex, documenting thatthe first example of 322 
the widespread SCP2 domain also functions in assisting chemical modifications of lipids. Our work 323 
highlights a remarkable bacterial metabolon synthesizing the hydrophobic ubiquinone molecule in the 324 
cytosol, and raises questions regarding the trafficking of isoprenoid lipids in and out of the membrane.  325 
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Figure legends: 526 
Figure 1: UQ biosynthesis activity and Ubi proteins localize in the soluble fraction of E. coli extracts. 527 
A) UQ biosynthesis pathway in E. coli.  The octaprenyl tail is represented by R on the biosynthetic 528 
intermediates. Abbreviations used are DMAPP for dimethylallyl pyrophosphate, IPP for isopentenyl 529 
pyrophosphate, 4-HB for 4-hydroxybenzoic acid, DDMQ8 for C2-demethyl-C6-demethoxy-ubiquinone 530 
8, DMQ8 for C6-demethoxy-ubiquinone 8 and UQ8 for ubiquinone 8. B) Synthesis of 13C6-UQ8 from 13C6-531 
OPP accumulated in ubiC cells. Cell free extracts, membrane and soluble fractions (resulting from 532 
150.000g ultracentrifugation) were supplemented with NADH and SAM and incubated at 30°C in 533 
aerobic conditions for the indicated time. The area of the 13C-UQ8 peak (m/z 764.5 at a retention time 534 
of 8 min., see Figure S1E) was normalized for the protein content of the fractions assayed. Results 535 
representative of three independent experiments. C) Immunodetection of Ubi-SPA proteins (-FLAG 536 
antibody) in soluble (s) and membrane (m) fractions of Ubi-SPA tagged strains (30 µg of total proteins) 537 
separated by SDS-PAGE. LamB and GAPDH are detected as controls. The ratio of the total content of 538 
each Ubi protein in entire soluble and membrane fractions is shown at the bottom (see Method 539 
Details). See also Figure S1. 540 
 541 
Figure 2: Seven Ubi proteins form a soluble Ubi complex. A) BN-PAGE electrophoresis and 542 
immunodetection of soluble fractions from the indicated Ubi-SPA strains (50 µg of total proteins). The 543 
membrane was first probed with -FLAG antibody, stripped and probed with -GAPDH. B) 544 
Immunodetection with -FLAG antibody of soluble fractions from the indicated Ubi-SPA strains after 545 
1D BN-PAGE and 2D SDS-PAGE (50 µg of total proteins). C) SDS-PAGE and western-blot analysis (-546 
FLAG antibody) of fractions recovered from glycerol gradients onto which the cytoplasm of the 547 
indicated Ubi-SPA cells were deposited. A typical distribution of GAPDH is also shown. Fractions 1 and 548 
22 correspond to the top and the bottom of the gradient, respectively (densities 1.02 and 1.11). Silver 549 
staining of gradient fractions analyzed by SDS-PAGE shows the distribution of total proteins (bottom).  550 
D) Separation by 1D BN-PAGE and 2D SDS-PAGE of glycerol gradient fractions 13-15 containing UbiG-551 
SPA and immunodetection with -FLAG antibody. The distribution of UbiG in all fractions of the 552 
gradient is shown (top). E) Interaction network between Ubi proteins constructed with Cytoscape 3 553 
from the results of the bacterial two hybrid experiments (Table S1). Line width is proportional to the 554 
value of the interaction and cut off value was three times background. Interaction of proteins with 555 
themselves (for example UbiA-UbiA) are not represented. Results representative of two independent 556 
experiments (A-C). See also Figure S2. 557 
 558 
Figure 3: Purification of the Ubi complex. A) Immunodetection with -CBP antibody of the purified 559 
Ubi complex after 1D BN-PAGE and 2D SDS-PAGE (E2 fraction of UbiE-SPA, see Figure S2F). B) Silver 560 
staining of SDS-PAGE with purified E2 fractions from indicated -SPA samples and WT controls. Asterisks 561 
mark bands common to –SPA samples and absent from WT. C) Venn diagram integrating the different 562 
proteins found to be specifically enriched with each bait as compared with the related negative 563 
controls using MS-based proteomics (Table S2). The names of the eight proteins enriched with all three 564 
tagged Ubi proteins are indicated. See also Figure S2. 565 
  566 
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Figure 4: The SCP2 domain of UbiJ binds UQ8 and its biosynthetic intermediates in the Ubi complex. 567 
A) Ratio of the abundance of octaprenyl lipids in the soluble fraction (SF, 150.000g supernatant) and 568 
the membrane fraction (MF) of WT cells grown in LB medium, mean ±SD (n=6). B) Glycerol gradient 569 
analysis of soluble extracts from UbiH-SPA cells and quantification of isoprenoid quinones in each 570 
fraction by HPLC-ECD-MS. Recovery calculated from the total content of all fractions compared to 571 
content of the UbiH-SPA soluble fraction deposited on top of the gradient. The western-blot showing 572 
the position of UbiH in the gradient is the same than in Figure 2C. C) Levels of OPP, DMQ8 and UQ8 in 573 
cells overexpressing or not UbiJ-K (n=4), see Figure S3C, **: p< 0.01, ***: p< 0.001, unpaired Student’s 574 
t test. D) Abundance of isoprenoid quinones in the indicated purified proteins (see Figure S3E), mean 575 
±SEM (n=2). See also Figure S3. 576 
 577 
Figure 5. Structure of UbiJ-SCP2 at 1.7 Å resolution. A) UbiJ-SCP2 appearing as a dimer within the 578 
asymetric unit, monomers contain a beta sheet consisting of 5 strands and 5 alpha helices similar to 579 
SCP2 family proteins (chain A in orange, chain B in teal). B) Yellow spheres represent the cavity found 580 
in UbiJ-SCP2 (cavity modelled using CAVER3 plugin for Pymol). C) Model of the cavity area of UbiJ-SCP2 581 
with the hydrophobic residues lining the cavity highlighted in yellow and showing unmodelled electron 582 
density (maps for 2FoFc are set at 1 σ [blue mesh]and for FoFc are set at 3 σ [green mesh]). D) Sequence 583 
for UbiJ-SCP2 with hydrophobic residues interfacing with the cavity pocket shown in yellow (cylinders 584 
represent α-helices, arrows β-strands). E) Hydrophobic cavities in UbiJ-SCP2 chain A (top) and chain B 585 
(middle), and comparison with ubiquinone 8 (bottom, taken from PDB: 5Y5S). The respective lengths 586 
are indicated. See also Figure S4 and S5. 587 
 588 
Figure 6: UbiJ is essential to the stability of the Ubi complex. A) Glycerol gradient analysis of soluble 589 
extracts from UbiG-SPA ∆ubiJ cells and quantification of UQ8 and OPP in each fraction.  Western-blots 590 
show the distribution of UbiG-SPA and the control GAPDH protein (see also Figure S6C-D, recovery 591 
calculated as in Figure 4B). B-C) Immunodetection with α-FLAG antibody of soluble fractions from the 592 
UbiH-SPA strain carrying deletions in the indicated ubi genes after BN-PAGE analysis (B) or 1D BN-PAGE 593 
and 2D SDS-PAGE (C). D-E) Immunodetection with α-FLAG antibody of soluble fractions from the 594 
indicated Ubi-SPA strain carrying deletions for ∆ubiJ (D) or ∆ubiK (E) after 1D BN-PAGE and 2D SDS-595 
PAGE. A representative result from 2 independent experiments is shown (B-E). F) UQ8 biosynthetic 596 
pathway (top) and proposed model of the physical organization of Ubi proteins and prenylated UQ8 597 
intermediates with respect to the inner membrane. The same representation is used for all 598 
polyprenylated compounds, irrespective of the substituents of the benzoquinone head group. 599 
Membrane-bound UbiA prenylates 4HB to yield OHB that localizes in the lipid bilayer. UbiB assists the 600 
extraction of OHB from the membrane and OHB is subsequently decarboxylated to OPP by UbiD-X. 601 
OPP is bound by UbiJ in the Ubi complex and the metabolon formed by the seven Ubi proteins circled 602 
in red synthesizes UQ8, which is ultimately delivered to the membrane, where it fulfills its physiological 603 
functions. See also Figure S6. 604 
  605 
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STAR Methods  606 
CONTACT FOR REAGENT AND RESOURCE SHARING 607 
Further information and requests for resources and reagents should be directed to and will be 608 
fulfilled by the Lead Contact, Fabien Pierrel (fabien.pierrel@univ-grenoble-alpes.fr) 609 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 610 
E. coli strains were stored frozen at -80°C in solutions containing 20% glycerol and revived by streaking 611 
on LB plates containing 1.6% bacto-agar (w/v) and incubating overnight at 37°C. Plates were kept at 612 
4°C for up to three weeks and colonies from the plates were used to inoculate overnight precultures 613 
in liquid medium. Large cultures were performed by inoculating fresh growth medium at OD600 0.05 614 
with the precultures. E. coli strains were grown in lysogeny broth (LB) medium at 37 °C in Erlenmeyer 615 
flasks filled to 1/10 of the maximal volume and shaken at 180 rpm, unless stated otherwise. For 616 
experiments using labelling with 13C7-4-HB, cells were grown in MSG medium, a minimal medium 617 
supplemented with 0.4% glycerol (w/v) (Alberge et al., 2015). All growth media were sterilized by 618 
autoclave and then ampicillin (50 mg/L), kanamycin (25 mg/L), and chloramphenicol (25 mg/L) were 619 
added from stocks (1000X solution sterilized through 0.22 µm filters and stored at -20°C), when 620 
needed. MSG medium was supplemented with 0.5% casaminoacids (w/v) and with 1/100 volume of a 621 
filter-sterile solution of 1mM CaCl2, 200 mM MgCl2, 1% thiamine (w/v).  622 
METHOD DETAILS 623 
Strain construction:  624 
All strains used in this study are listed in Table S5.  625 
Construction of SPA strains:  626 
The DY330 ubiC-SPA strain encompassing the SPA tag DNA sequence and the kanamycin antibiotic 627 
resistance marker cassette (KanR) was used as a template in polymerase chain reaction (PCR) 628 
amplification. A 5-ubiD, E, I, J, K -SPA gene-specific forward primer (Table S6), located immediately 629 
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upstream of the ubi stop codon, and a 3-ubiD, E, I, J, K -SPA gene-specific reverse primer, located 630 
immediately downstream of the target gene stop codon, were used to amplify the SPA tag and KanR 631 
cassette. The purified PCR products were subsequently integrated at the 3′ end of ubi genes or atpB 632 
gene in the BW25113 strain in which the λ-Red recombination machinery is expressed. Finally, the ubi–633 
SPA–Kan cassettes were transduced through P1 phage from BW25113 to MG1655. When DY330 SPA-634 
tagged strains were available (Hu et al., 2009), the ubi–SPA–Kan cassettes were transduced to MG1655 635 
through P1 phage.  636 
Construction of knock-out strains:  637 
The ubiC::Kan, ubiE::Kan, ubiF::Kan, ubiG::Kan mutations (from the BW25113 strains, Keio 638 
library) and ubiJ::Kan, ubiK::Kan mutations were transduced into the desired MG1655 strain by P1 639 
transduction. 640 
Plasmid construction:  641 
The two-hybrid plasmids were constructed by inserting the ubi ORF sequences in pT18 and pT25 642 
plasmids, using the oligonucleotides indicated in Table S6. Briefly, the ubi gene fragments were 643 
obtained by PCR amplification using the genomic DNA of MG1655 as template and the oligonucleotides 644 
5-XhaI ubi and 3-XbaI ubi. PCR products were XbaI-digested and inserted into XbaI-digested pT18 or 645 
pT25 plasmids, yielding the pT18-ubi and pT25-ubi plasmids, respectively. All plasmids were verified 646 
using DNA sequencing.  647 
Bacterial two-hybrid reporter system: 648 
 The bacterial two-hybrid reporter system is based on functional complementation of the two domains 649 
of Bordetella pertussis adenylate cyclase, T18 and T25, expressed separately from two compatible 650 
plasmids (Karimova et al., 1998). Adenylate cyclase activity is restored only when proteins fused to T18 651 
and T25 interact. Fusions were constructed with T18 and T25 present at the N-terminal of Ubi proteins. 652 
Functional reconstitution of B. pertussis adenylate cyclase in an E. coli _cya lac_ strain was monitored 653 
by assaying the activity of a cAMP-CRP-dependent lac promoter of a chromosomally encoded lac 654 
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operon. In addition to testing the pair of proteins of interest, positive controls were performed with 655 
T25-zip and T18-zip plasmids. Negative controls were performed with the two empty T18 and T25 656 
plasmids and also with each protein of interest against the empty T18 or T25 plasmids. 657 
The interaction network of Ubi proteins in Figure 1E was constructed with Cytoscape 3 (Su et al., 2014) 658 
from the results of the bacterial two hybrid experiments (Table S1), excluding values less than 3 times 659 
above background.  660 
Preparation of soluble and membrane fractions:  661 
Ubi-SPA strains were cultured in 1 L of LB medium (2 L flasks) with shaking (200 rpm) at 37°C. When 662 
OD600 reached 1.5-2, cells were cooled down on ice with occasional shaking and harvested by 663 
centrifugation at 5,000 g for 20 min at 4°C. The cell pellet was washed with 10 mL cold water, the same 664 
centrifugation was repeated and the pellet was frozen in liquid nitrogen, then stored at -80°C. The cell 665 
pellet was resuspended in 30 mL buffer A (50 mM Imidazole/HCl pH=7, 50 mM NaCl, 1 mM EDTA, 1 666 
mM PMSF, 250 mM sucrose; (adapted from (Wittig et al., 2006))) and the cells were ruptured by 3 667 
passages through French press (1,500 psi). Cell debris were eliminated by centrifugation at 3,200 g for 668 
10 min at 4°C, then 20 mL of the supernatant was subjected to ultracentrifugation at 120,000 g for 1h 669 
at 4°C.  The supernatant after ultracentrifugation corresponds to the soluble fraction. The pellet was 670 
resuspended in 2 mL of buffer A to yield the membrane fraction. Aliquots of both fractions were frozen 671 
with liquid nitrogen and stored at -80°C. 672 
Protein concentration and SDS-PAGE:  673 
Protein concentrations were determined by the bicinchoninic acid assay (Thermo). 30 μg of total 674 
protein were analyzed on 12% acrylamide SDS-PAGE gel and electrophoresis was performed at 20 mA 675 
for 45 min. Prestained Protein Ladder (Euromedex) was used as molecular weight marker.   676 
Blue Native-PAGE:  677 
Native PAGE sample additive (Life Technologies) was added to the soluble fractions (50 µg of proteins) 678 
and BN-PAGE was performed using Native PAGE 3–12% Bis–Tris gels (1.0 mm × 10 wells; Life 679 
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Technologies). The BN-PAGE system consisted of two compartments: the internal one contained the 680 
cathode buffer (50 mM tricine, 7.5 mM imidazole, 0.02% coomasie blue G250, pH=7) whereas the 681 
external one contained the NativePAGE running buffer (50 mM Bis–Tris pH=7, 50 mM tricine, Life 682 
Technologies). Electrophoresis was performed at 4°C using 3 tensions: 100V for 20 min allowing 683 
proteins to enter the gel, 200V for 30 min then 300V until the migration front reached the lower limit 684 
of the gel (~1h). Proteins were transferred onto an immobilon PVDF membrane pre-activated for 2 min 685 
with methanol. Transfer was performed in buffer B (50 mM Tricine, 7.5 mM imidazole, pH=7) for 3h at 686 
4°C with 20 mV tension. At the end of the transfer, the PVDF membrane was discolored by rinsing 687 
several times with a mixture of 20% methanol and 10% acetic acid in order to visualize the molecular 688 
weight marker (NativeMark, Life Technologies). The position of marker bands on the membrane was 689 
marked with pencil and full discoloration of the membrane was obtained with 100% methanol. The 690 
membrane was further processed for western-blotting.  691 
Two dimensional BN-PAGE/SDS-PAGE: 692 
After the BN-PAGE was completed, gel lanes were cut out of the gel, soaked in SDS-PAGE running 693 
buffer (0.375 M Tris-HCl, pH 8.8, glycine 0.192 M, SDS 10%) for 15 min and then loaded onto a 12.5% 694 
acrylamide SDS gel of 1.5 mm thickness. 5 µL of molecular weight marker (prestained protein ladder) 695 
was deposited on a Whatman paper, which was positioned next to the BN-PAGE fragment. BN gel and 696 
SDS gel were glued together using buffer C (0.5% agarose dissolved in SDS running buffer and few 697 
drops of 0.5% bromophenol blue). Migration was performed at 20 mA until the migration front reached 698 
the bottom of the gel. Transfer was performed using trans-blot turbo system (Bio-Rad) 17 V, 10 min.  699 
Western-blot analyses:  700 
After transfer, membranes were saturated with 5% milk in PBST (Phosphate-buffered saline, 0.2% 701 
Tween-20) for 30 min, rinsed 3 times in PBST and incubated overnight with the primary antibody in 702 
PBST at 4°C on a rotary table. Primary antibodies were used at the following dilutions: α-FLAG antibody, 703 
1/5000; α-CBP, 1/3000; α-GAPDH, 1/5000; α-LamB, 1/3000. Immunodetection was performed using 704 
goat anti-rabbit HRP-conjugated or goat anti-mouse HRP-conjugated and the Clarity Western ECL 705 
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substrate (BioRad). Images were acquired on a ChemiDoc XRS system with the Image Lab software 706 
(BioRad). When detection with a second antibody was needed, the membrane was stripped by three 707 
successive incubations in stripping buffer (glycine-HCl 1.5% (m/V) pH 2.2, SDS 0.1% (m/V), Tween 1% 708 
(V/V)), then rinsed in PBST and saturated with 5% milk in PBST.  709 
The s/m ratio in Figure 1C were calculated as follows. The intensity of each protein band (quantified 710 
from the western-blot with Image Lab software) was multiplied by the total protein content of the 711 
corresponding fraction (typically, 18 mL at 5 mg protein/mL for FS and 2 mL at 19 mg protein/mL 712 
for FM) to estimate the total content of Ubi-SPA proteins in s and m fractions. Then, we computed the 713 
quotient of the values obtained for s and m for each Ubi-SPA protein.    714 
 715 
Silver staining:  716 
The SDS-gel was placed in fixing solution (50% methanol, 5% acetic acid) and agitated gently on a rotary 717 
shaker for 20 min. The gel was then rinsed in 50% methanol for 10 min, in water for 10 min and was 718 
agitated gently in 100 mL of 0.02% sodium-thiosulfate for 1 min, followed by two washing steps with 719 
water for 1 min. The gel was incubated for 20 min in 200 mL of 0.2% silver nitrate solution 720 
supplemented with 0.08% formaldehyde. The gel was washed with distilled water for 20 sec to remove 721 
the excess silver nitrate and was then placed in 50 mL of developing solution (2% sodium carbonate 722 
and 0.04% formaldehyde). When the desired intensity was obtained, the gel was transferred to 5% 723 
acetic acid for 20 min to stop the reaction. After rinsing with distilled water for 10 min, the gel was 724 
stored in 5% glycerol. 725 
Overexpression and purification of proteins:  726 
The UbiJ(6his)-UbiK and UbiK proteins were overexpressed and purified as previously described 727 
(Loiseau et al., 2017). Overexpression of UbiJ-SCP2 was performed in BL21 (DE3) E.coli strain 728 
transformed with the previously reported pETDuet-ubiJ(121–201) (Loiseau et al., 2017). Cells were 729 
grown with shaking (200 rpm) at 37°C, in lysogeny broth (LB) medium containing ampicillin (100 730 
µg/ml), until they reached OD600 = 0.4, at which point overexpression was induced by addition of 731 
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lactose (5.8 mM). After induction, cells were grown for 17 hours at 16°C, and then harvested by 732 
centrifugation at 5,000 g for 10 min. All subsequent operations were carried out at 4°C. Cells were 733 
resuspended in 5 volumes of buffer D (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 734 
phenylmethylsulfonyl fluoride) and lyzed by sonication (Branson Digital Sonifier, Amplitude 40% for 10 735 
min). Crude extracts were then submitted to ultracentrifugation at 180,000 g for 90 min (Optima XPN-736 
80, rotor 50.2 Ti, Beckman Coulter). The resulting supernatant was loaded onto a Hitrap Chelating HP 737 
column (5 mL, GE Healthcare) equilibrated with buffer D. The Hitrap Chelating HP column was washed 738 
with buffer D supplemented with 25 mM imidazole and subsequently eluted with 300 mM imidazole 739 
in buffer D. The most pure UbiJ-SCP2 fractions were pooled and loaded onto a HiLoad 26/600 Superdex 740 
75 pg equilibrated with 50 mM Tris-HCl pH7.5, 150 mM NaCl. The main peak fractions were pooled, 741 
frozen in liquid N2 and stored at - 80°C. 742 
Crystallization:  743 
Crystals were grown at 19 °C by the hanging drop vapor diffusion method. Initial reservoir 744 
crystallization hit consisted of 18% PEG 8000, 200 mM calcium acetate hydrate with 100 mM sodium 745 
cacodylate trihydrate pH 6.5. Crystal growth was observed in high protein concentration of no less 746 
than 15 mg/mL. The reservoir condition was optimized for best crystal growth to consist of 11% PEG 747 
8000, 225 mM calcium chloride with 100 mM MMT buffer pH 9 (MMT is DL-malic acid/MES/Tris base 748 
mixed at a ratio of 1/2/2 and pH-adjusted with sodium hydroxide). Rod-like crystals grew within the 749 
precipitate overnight. All crystals were cryoprotected in a solution similar to the reservoir solution 750 
containing 20 % PEG 400 prior to flash freezing. Best diffraction of these crystals led to the initial 2.5 Å 751 
dataset (PDB code 6H6P). Derivatisation of these crystals led to lower resolution diffraction and poor 752 
anomalous signal. These crystals were used for seeding which led to more consistent crystal shape 753 
however after these conditions had been left for over a month a more cubic shaped crystal form 754 
appeared in the condition. This new crystal form diffracted to 1.7 Å (PDB code 6H6O) and when used 755 
for seeding resulted in cubic crystal growth at a much lower protein concentration of 2.5 mg/ml. These 756 
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crystals natively diffracted well and were used for derivatisation using various heavy atom compounds. 757 
Polyvalan crystallophore No1 was used in cocrystallisation and resulted in crystals diffracting to 2 Å 758 
with significant anomalous signal allowing phasing of the data for structure determination (PDB code 759 
6H6N).  760 
Data collection and structure determination:  761 
All crystals belong to the space group P212121. The 2.5 Å dataset has a unit cell parameters of a= 47.69 762 
Å; b= 94.55 Å; c= 115.66 Å, and four molecules per asymmetric unit. The 1.7 Å has a unit cell parameters 763 
of a= 48.6 Å; b= 67.87 Å; c= 74.60 Å, and the 2.05 Å dataset has a unit cell parameters of a= 48.30 Å; 764 
b= 67.93 Å; c= 73.08 Å, and both have two molecules per asymmetric unit. The 2.5 Å X-ray diffraction 765 
data were collected from single crystal at 100 K on the EIGER X 9M detector on beamline Proxima 2 at 766 
the Soleil synchrotron radiation source, Paris. The 1.7 Å and 2.05 Å X-ray diffraction data were collected 767 
from single crystals at 100 K on the Pilatus detector on beamline Proxima 1 at the Soleil synchrotron 768 
radiation source, Paris. Data were processed and scaled using the package XDS (Kabsch, 2010). 769 
Anisotropy and diffraction limits were set using the program STARANISO (Bricogne et al., 2017). Phases 770 
were obtained from 2 Terbium sites in the 2.05 Å dataset using SHELX (Sheldrick, 2015). Model was 771 
automatically built using Buccaneer and further manual building using the program Coot (Cowtan, 772 
2006; Emsley et al., 2010) with refinement performed using BUSTER (Bricogne et al., 2017). This model 773 
was then used to molecular replace the two other datasets for their further modelling and refinement 774 
using the same methods. The CCP4 software suite was also used in processing of data and Pymol was 775 
used in production of images including the CAVER3 plugin for cavities (Chovancova et al., 2012; Pavelka 776 
et al., 2016; Winn et al., 2011). 777 
13C6-UQ8 biosynthesis activity assay:  778 
ubiC cells from an overnight preculture were inoculated at OD600 0.15 in 100 mL MSG medium. The 779 
cells were cultured at 37°C, 200 rpm until OD600 1, at which point chloramphenicol (200 µg/mL) was 780 
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added and incubation continued for 20 min. Then, the cells were transferred to a screw cap flask fitted 781 
with two plastic tubing through which the culture was purge with argon for 5 min. 10 µM 13C7-4-HB 782 
was added, the cells were maintained under argon at 37°C and initial experiments following the 783 
biosynthesis of 13C6-OPP at different incubation time established that 10 min labeling with 13C7-4-HB 784 
was optimal (Figure S1B). Cells were cooled down on ice under argon. In all subsequent steps carried 785 
out under normal atmosphere, care was taken to maintain the cells at 4°C in order to avoid conversion 786 
of 13C6-OPP into 13C6-UQ8. Cold cells were collected by centrifugation at 3,200 g, 4°C, 10 min and 787 
resuspended in 10 mL cold standard buffer (50 mM Tricine pH 7.5, 5 mM MgSO4, 10 mM β-788 
mercaptoethanol).  789 
For the in vivo assay, the cells were diluted five-fold in MSG medium containing 200 µg/mL 790 
chloramphenicol and incubated at 37°C either in normal atmosphere with 180 rpm shaking or under 791 
argon, a condition in which 13C6-UQ8 did not form. For the in vitro assay, cells in standard buffer were 792 
ruptured by 3 passages through French press (1500 psi) and debris were eliminated by centrifugation 793 
at 8,000 g for 20 min at 4°C. The cell free lysate was either directly assayed by adding 2 mM NADH, 2 794 
mM SAM and incubating at 30°C with occasional shaking or ultracentrifuged at 150,000 g, 4°C for 90 795 
min. The supernatant corresponding to the soluble fraction was taken and the membrane pellet was 796 
resuspended in a volume of standard buffer equal to that of the supernatant. 300 µL fractions were 797 
assayed by adding 2 mM NADH and 2 mM SAM and incubating at 30°C with occasional shaking. The 798 
reactions were stopped by placing the samples at -20°C prior to lipid extraction and HPLC-ECD-MS 799 
analysis. 800 
Lipid extraction and quinone analysis:  801 
Quinone extraction from cell pellets and quantification by HPLC-ECD-MS analyses were performed as 802 
previously described (Loiseau et al., 2017). Aliquots of glycerol gradient fractions (250 µL) or of 803 
membrane (100 µL) and soluble fractions (400 µL) were extracted twice in glass tubes with 3 mL 804 
methanol, 30 µL KCl 3M and 2*2 mL p-ether. Depending on the separation needed, mobile phase 1 805 
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(40% ethanol, 40% acetonitrile and 20% of a mix of 90% isopropanol, 10% ammonium acetate (1 M), 806 
0.1% TFA) or mobile phase 2 (50% methanol, 40% ethanol and 10% of a mix of 90% isopropanol, 10% 807 
ammonium acetate (1 M), 0.1% TFA) were used at a flow rate of 1 mL/min with a BetaBasic-18 column. 808 
MS detection was on a MSQ spectrometer (Thermo Scientific) and electrospray ionization in positive 809 
mode used a probe temperature of 400°C and a cone voltage of 80V. Single ion monitoring (SIM) 810 
detected the following compounds: OPP (M+NH4+), m/z 656.0-656.8, 5-10 min, scan time 0.2 s;  13C6-811 
OPP (M+ NH4+), m/z 662.0-662.8, 5-10 min, scan time 0.2 s; DMQ8 (M+NH4+), m/z 714.0-714.8, 6-10 812 
min, scan time 0.2 s; UQ8 (M+NH4+), m/z 744.0-744.8, 6-10 min, scan time 0.2 s; 13C6-UQ8 (M+Na+), m/z 813 
755.0-755.8, 6-10 min, scan time 0.3 s; UQ10 (M+NH4+), m/z 880.2-881.2, 10-17 min, scan time 0.2 s. 814 
For some analyses, 0.1mM methylamine was added to the methanol of mobile phase 2, in which case 815 
the probe temperature was 450°C and SIMs were set as follows: UQ8 (M+CH3NH3+), m/z 758.0-758.8, 816 
6-10 min, scan time 0.2 s; 13C6-UQ8 (M+CH3NH3+), m/z 764.0-764.8, 6-10 min, scan time 0.3 s; UQ10 817 
(M+CH3NH3+), m/z 894.2-895.2, 10-17 min, scan time 0.2 s. MS spectra were recorded between m/z 818 
600 and 900 with a scan time of 0.3 s. UV detection at 247 nm was used to quantify DMK8 and MK8. 819 
Peak areas were corrected for sample loss during extraction on the basis of the recovery of the UQ10 820 
internal standard and were then normalized either to cell’s wet weight, or to total proteins (soluble 821 
and membrane fractions), or to quantity of purified protein, or to the total content of the fraction 822 
deposited on glycerol gradients. The peak of UQ8 obtained with electrochemical detection was 823 
quantified with a standard curve of UQ10  (Hajj Chehade et al., 2013).   824 
Purification of the Ubi complex:  825 
Ubi-SPA and WT strains were cultured in 1 L LB medium (2 L flasks) with shaking (200 rpm) at 37°C until 826 
OD600 = 2.5-3. Soluble fractions were prepared in 10 mL lysis buffer (10 mM Tris-HCl pH 7.9, 100 mM 827 
NaCl, 10 mM DTT) with 1X anti-protease (sigmaFAST protease inhibitor). The subsequent two steps 828 
purification procedure was carried out at 4°C with ice cold buffers and we indicate below the names 829 
of the fractions analyzed in Figure S2c-g. 100 µL of anti-Flag M2 agarose beads (Sigma) were first 830 
washed with 10 mL lysis buffer (without DTT) and the beads were added to the ultracentrifugation 831 
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supernatant in a 15 mL Falcon tube. The mixture was rotated moderately (20 rpm) for 3h, then 832 
transferred to a 10 mL disposable chromatography column (EconoPac, BioRad) and the unbound 833 
material was eluted by gravity (FT-FLAG). The resin was washed with 30 mL lysis buffer (W1) followed 834 
by 30 mL TEV cleavage buffer (50 mM Tris-HCl pH 7.9, 100 mM NaCl and 0.2 mM EDTA) (W2). The 3X 835 
FLAG motif was cleaved by adding 500 µL of TEV cleavage buffer containing 1X anti-protease, 1 mM 836 
DTT and 50 µg Tobacco Etch Virus protease (TEV) and by incubating overnight under rotation. The next 837 
day, the eluate was drained into a fresh Eppendorf tube (El-TEV). 838 
Prior to use, 100 µL of Calmodulin-Sepharose 4B beads were transferred into a 15 mL tube (Falcon), 839 
washed twice in batch with 10 mL of CBP binding buffer (10 mM Tris-HCl pH 7.9, 100 mM NaCl and 2 840 
mM CaCl2) and the beads were suspended in 500 µL of TEV cleavage buffer containing 2 mM CaCl2 and 841 
10 mM β -mercaptoethanol. The beads suspension was added to the eluate recovered after TEV 842 
cleavage and the mixture was rotated for 3h in an Eppendorf tube. The sample was transferred to a 843 
1.5 mL chromatography column (Mini-columns, Evergreen Scientific) and the unbound fraction was 844 
drained by gravity (FT-CBP). The beads were then washed 5 times with 500 µL of calmodulin washing 845 
buffer (10 mM Tris-HCl pH 7.9, 100 mM NaCl, 1 mM CaCl2, 10 mM β-mercaptoethanol) (W1-W5). The 846 
bound proteins were eluted in five fractions of 100 µL using the calmodulin elution buffer (10 mM Tris-847 
HCl pH 7.9, 200 mM NaCl, 3 mM EGTA, 10 mM β-mercaptoethanol) (E1-E5).  848 
Glycerol gradient fractionation:  849 
1 mL soluble fractions of Ubi-SPA strains were deposited on 10 mL linear glycerol gradients prepared 850 
using two glycerol solutions (densities  1.025 and 1.110) in modified buffer A (50 mM Imidazole/HCl 851 
pH=7, 50 mM NaCl, 1 mM EDTA). Fractions of 0.5 mL were collected manually from the bottom of the 852 
tubes after centrifugation for 15h at 120,000 g and 4°C in a swinging bucket rotor (Beckman SW-41). 853 
15 µL of each fraction were analyzed by SDS-PAGE, SPA-tagged proteins were immunodetected and 854 
the reproducibility of the gradients was verified by immunodetection of GAPDH. Quinone 855 
quantification in glycerol gradient fractions was measured from 200 µL aliquots.  856 
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Mass spectrometry-based proteomic analyses: 857 
Proteins were in-gel digested using trypsin as described in (Barral et al., 2017).  The resulting peptides 858 
were analyzed by online nano-liquid chromatography coupled to tandem mass spectrometry (Ultimate 859 
3000 nano RSLC and Q-Exactive HF, Thermo Scientific) using a 120-min gradient. Peptides were 860 
sampled on a 300 µm x 5 mm PepMap C18 precolumn (Thermo Scientific) and separated on a 75 µm x 861 
250 mm C18 column (Reprosil-Pur 120 C18-AQ, 1.9 μm, Dr. Maisch). MS and MS/MS data were 862 
acquired using Xcalibur (Thermo Scientific). Peptides and proteins were identified using Mascot 863 
(version 2.6.0) through concomitant searches against Uniprot (Escherichia coli K12 taxonomy), classical 864 
contaminants database (homemade) and the corresponding reversed databases. The Proline software 865 
(http://proline.profiproteomics.fr) was used to filter the results (conservation of rank 1 peptides, 866 
peptide identification FDR < 1% as calculated on peptide scores by employing the reverse database 867 
strategy, minimum peptide score of 25, and minimum of 1 specific peptide per identified protein 868 
group) before performing a compilation, grouping and comparison of the protein groups from the 869 
different samples. Proteins were considered as potential partners of the bait if they were identified 870 
only in the positive co-IPs with a minimum of 5 specific spectral counts or enriched at least 10 times in 871 
positive co-IPs compared to control ones on the basis of specific spectral counts. 872 
 873 
QUANTIFICATION AND STATISTICAL ANALYSIS 874 
See each individual method and figure legends for the associated statistical analysis. In general, p-875 
values were calculated using an unpaired, two-tailed, Student’s t-test. In all cases, n represents 876 
independent replicates of an experiment. 877 
 878 
DATA AND SOFTWARE AVAILABILITY 879 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 880 
via the PRIDE partner repository with the dataset identifier PXD010396.  881 
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The crystal structures of the SCP2 domain of UbiJ have been deposited in the Protein Data Bank PDB 882 
with the identifiers 6H6N, 6H6O and 6H6P. 883 
Supplemental Information  884 
Supplemental information contains 6 supplemental figures and 6 supplemental tables.  885 
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 KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
α-FLAG  Sigma Aldrich Cat A2220 
(RRID:AB_1006303
5) 
α-Calmodulin Binding Peptide Genscript Cat A00635-40 
(RRID:AB_914284) 
α-GAPDH Covalab Cat 00006357 
α-LamB A. Meinke, Intercell 
AG 
N/A 
goat anti-rabbit HRP-conjugated Covalab Cat# 00030130 
goat anti-mouse HRP-conjugated Covalab Cat# 00030133 
   
Bacterial and Virus Strains  
E. coli MG1655 ATCC ATCC 47076 
E. coli BW25113 National BioResource 
Project 
http://nbrp.jp/ 
search for ME9062 
E. coli BL21 (DE3) Merck Millipore Cat# 69450-3 
E. coli BTH101 (Karimova et al., 1998) N/A 
E. coli DY330 (Hu et al., 2009) N/A 
   
Biological Samples   
   
Chemicals, Peptides, and Recombinant Proteins 
13C7-4-HB Sigma Aldrich Cat 587869 
NADH Sigma Aldrich Cat 43420 
S-Adenosylmethionine Sigma Aldrich Cat A2408 
anti-Flag M2 agarose beads Sigma Aldrich Cat A2220 
Calmodulin-Sepharose 4B beads Sigma Aldrich Cat GE17-0529-01 
sigmaFAST protease inhibitor Sigma Aldrich Cat S8830 
Prestained (Two Colors) Protein Ladder Plus (10-
250Kda) 
Euromedex Cat# 06P-0211  
Native PAGE sample additive Life Technologies Cat BN2003 
Native PAGE 3–12% Bis–Tris gels Life Technologies Cat BN1001BOX 
Native PAGE 20X Running Buffer Life Technologies Cat BN2001 
NativeMark protein ladder Life Technologies Cat LC0725 
Polyvalan crystallophore No1 Molecular Dimensions Cat MD2-81 
Purified UbiK protein This study N/A 
Purified UbiJ-SCP2 protein This study N/A 
Purified UbiJ-K complex This study N/A 
Sequencing Grade Modified Trypsin Promega V5111 
Dithiothreitol Fisher Scientific BP172 
Iodoacetamide Sigma Aldrich I1149 
Ammonium bicarbonate Sigma Aldrich A6141 
Formic acid EMD Millipore 
Chemical 
1.11670.0250 
Acetonitrile Sigma Aldrich 34851-M 
   
Key Resource Table
 Critical Commercial Assays 
   
Deposited Data 
mass spectrometry proteomics data This study http://www.proteome
xchange.org 
PXD010396 
X-ray structure of UbiJ-SCP2, 2.1 Å This study http://www.rcsb.org/ 
PDB ID: 6H6N 
X-ray structure of UbiJ-SCP2, 1.7 Å This study PDB ID: 6H6O  
X-ray structure of UbiJ-SCP2, 2.5 Å This study PDB ID: 6H6P 
   
Experimental Models: Cell Lines 
   
Experimental Models: Organisms/Strains 
For all E. coli strains, see Table S5   
   
Oligonucleotides 
For all primers, see Table S6 This paper N/A 
   
Recombinant DNA 
pETDuet-6his-ubiJ/ubiK (Loiseau et al., 2017) N/A 
pETDuet-ubiJ(Δ121–201) (Loiseau et al., 2017) N/A 
pETDuet-ubiK no-tag (Loiseau et al., 2017) N/A 
pT18 (Karimova et al., 1998) N/A 
pT25 (Karimova et al., 1998) N/A 
pT18-ubiA This paper N/A 
pT18-ubiB This paper N/A 
pT18-ubiC This paper N/A 
pT18-ubiD This paper N/A 
pT18-ubiE This paper N/A 
pT18-ubiF This paper N/A 
pT18-ubiG This paper N/A 
pT18-ubiH This paper N/A 
pT18-ubiI This paper N/A 
pT18-ubiJ This paper N/A 
pT18-ubiK This paper N/A 
pT18-ubiX This paper N/A 
pT25-ubiA This paper N/A 
pT25-ubiB This paper N/A 
pT25-ubiC This paper N/A 
pT25-ubiD This paper N/A 
pT25-ubiE This paper N/A 
pT25-ubiF This paper N/A 
pT25-ubiG This paper N/A 
pT25-ubiH This paper N/A 
pT25-ubiI This paper N/A 
pT25-ubiJ This paper N/A 
pT25-ubiK This paper N/A 
 pT25-ubiX This paper N/A 
   
   
Software and Algorithms 
XDS (Kabsch, 2010) http://xds.mpimf-
heidelberg.mpg.de/ 
STARANISO (Bricogne et al., 2017) http://staraniso.globa
lphasing.org/cgi-
bin/staraniso.cgi 
SHELXL (Sheldrick, 2015) http://shelx.uni-
goettingen.de/ 
Coot (Emsley et al, 2010) https://www2.mrc-
lmb.cam.ac.uk/perso
nal/pemsley/coot/ 
BUSTER (Bricogne et al., 2017) https://www.globalph
asing.com/buster/ 
CCP4 (Winn et al., 2011) http://www.ccp4.ac.u
k/ 
Pymol Schrödinger, LLC https://pymol.org/2/ 
CAVER3 (Chovancova et al., 
2012) 
https://www.caver.cz
/ 
Mascot Distiller Matrix Science http://www.matrixsci
ence.com/ 
Mascot Matrix Science http://www.matrixsci
ence.com/ 
Proline  Open source http://www.profiprote
omics.fr/proline 
Xcalibur Thermo Fisher 
Scientific 
https://www.thermofi
sher.com 
Cytoscape 3.0 (Su et al., 2014) https://cytoscape.org 
   
Other 
Liquid chromatography Thermo Scientific UltiMate 3000 
RSLCnano System 
Reprosil-Pur 120 C18-AQ, 1.9 μm, 250 mm x 75 μm Dr. Maisch GmbH r119.aq. 
Mass spectrometer Thermo Scientific Q Exactive Plus 
BetaBasic-18, 150 mm x 4.6 mm, 5μm Thermo Scientific Cat# 71505-154630 
Hitrap Chelating HP column GE Healthcare Cat GE17-0408-01 
 
 
 
FIGURE S1 
 
Figure S1 related to figure 1: A) Structures of Ubiquinone (UQ) and menaquinone (MK) with the head 
groups in black. The length of the polyprenyl tail (in red) can vary between species (n=6-10). B) 
Accumulation of 13C6-OPP (M+ NH4+) after addition of 13C7-4-HB to ∆ubiC cells incubated in anaerobic 
conditions. C) Conversion of 13C6-OPP (M+ NH4+) into 13C6-UQ8 (M+ Na+) by cells incubated in air or 
maintained under argon. D) Synthesis of 13C6-UQ8 (M+CH3NH3+) by cell free extracts incubated in air with 
or without addition of NADH and SAM. E) HPLC analysis and single ion monitoring (m/z=764.5, M+CH3NH3+) 
of 13C6-UQ8 in cytoplasmic fractions from ∆ubiC cells preloaded with 13C-OPP and incubated in air for the 
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indicated time in the presence of NADH and SAM.  Results shown are representative of two (B, C) or three 
independent experiments (D, E). F) Schematic representation of a Ubi protein fused to the SPA tag, a 
repetition of 3 FLAG sequences separated from a CBP (Calmodulin Binding Protein) domain by a TEV clivage 
site (TEV: Tobacco Etch Virus). G) HPLC-ECD quantification of cellular UQ8 content of E. coli strains carrying 
Ubi proteins endogenously tagged with SPA (mean ±SEM, n=3, *: p< 0.05, **: p< 0.01, unpaired Student’s 
t test). The UQ8 decrease in UbiH-SPA and UbiJ-SPA cells is statistically significant but nevertheless reflects 
that the UbiH-SPA and UbiJ-SPA proteins remain partially functional since a complete inactivation would 
cause a lack of UQ8, as observed in ubiH and ubiJ knock-out cells.  
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Figure S2  
 
Figure S2 related to figure 2 and 3: A) BN-PAGE analysis and immunodetection of soluble fractions from 
the indicated Ubi-SPA strains (50 µg of total proteins). The membrane was first probed with α-CBP 
antibody, stripped and probed with α-GAPDH (loading control). B) Immunodetection of the control GAPDH 
protein after stripping the α-FLAG antibody from the membranes presented in Figure 2B. C-D) 20 uL 
aliquots of soluble fraction (SF), flow-through (FT), washes 1 and 2 (W1, W2), and eluates after TEV 
digestion (El-TEV) collected during the anti-FLAG purification step were analyzed by SDS-PAGE and the gel 
was colored by silver staining (extracts from the UbiE-SPA strain (C) and from the WT strain (D)). E) 
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Western-blot analysis with α-CBP antibody of samples described in C-D. Sizes of the UbiE-SPA protein 
before and after cleavage by TEV are indicated with blue and red arrows, respectively. Asterisks mark 
longer exposures (C-E). F-G) SDS-PAGE analysis and silver staining of fractions collected during the 
calmodulin purification step: washes 1, 3, 5 (W1, W3, W5) and eluates 1-4 (E1-E4) from purification with 
UbiE-SPA (F) and WT (G) samples. H) Western-blot analysis with α-CBP antibody of samples described in 
F. I) UQ8 quantification in ∆blc and WT strains (mean ±SEM, n=4).  
 
 
Figure S3 
 
Figure S3 related to figure 4: A-B) Glycerol gradient analysis of soluble extracts from UbiJ-SPA and UbiF-
SPA cells, and quantification of isoprenoid quinones in each fraction (see also Figure 4B). Western-blot are 
the same than in figure 2C. C) HPLC-ECD analyses (mobile phase 2) of lipid extracts from 1 mg of the E. coli 
cells containing an empty vector (vec) or overexpressing UbiJ(6His)-K and grown in LB medium (UQ10 used 
as standard), DMK8 for C2-demethylmenaquinone 8. D) SDS-PAGE analysis and coomassie blue staining of 
purified UbiK, UbiJ-K and UbiJ-SCP2. E) HPLC-ECD analyses (mobile phase 2) of lipids extracted from 4 
nmoles of purified proteins (UQ10 used as standard). 
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Figure S4 
 
 
 
Figure S4 related to figure 5: Stick model of the structure of UbiJ-SCP2 at 1.7 Å resolution with electron 
density maps. A) UbiJ-SCP2 dimer with maps for 2FoFc set at 1 σ (blue mesh) and for FoFc set at 3 σ (green 
mesh). B) Zoomed in region of chain A with maps for 2FoFc set at 1 σ. (chain A shown in orange, chain B in 
teal, waters shown as red spheres, calcium shown as green spheres). 
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Figure S5 
 
Figure S5 related to figure 5: Sequence alignment of UbiJ-SCP2 domains taken from various bacterial 
strains. Residues lining the hydrophobic cavity highlighted in figure 5c are indicated by *. NCBI sequence 
numbers: NP_253751.1, WP_005755273.1, NP_229743.1, NP_407227.1, NP_418278.1, NP_462856.1 
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Figure S6 
 
Figure S6 related to figure 6: A) UQ8 and OPP content (normalized to cells wet weight) of WT and ∆ubiJ 
cells grown in LB medium. B, E) Immunodetection of Ubi-SPA proteins (α-FLAG antibody) in the soluble 
fractions of the indicated strains (25 µg of proteins), with GAPDH as control. C-D) Glycerol gradient 
analysis of soluble extracts from UbiH-SPA ∆ubiJ cells (C) or UbiF-SPA ∆ubiJ cells (D) and quantification of 
OPP and UQ8 in each fraction by HPLC-ECD-MS. Immunodetection with α-FLAG antibody showing the 
position UbiH-SPA and UbiF-SPA in fractions of the glycerol gradient (see also Figure 6A). F) HPLC-ECD 
analyses (mobile phase 1) of lipid extracts from 1 mg of the indicated E. coli cells grown in LB medium 
(UQ10 used as standard).  
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Table S1 related to figure 2E: Values of the bacterial two-hybrid assay, provided as separate excel file 
Table S2 related to figure 3: Results of proteomic analysis, provided as separate excel file 
Table S3 related to figure 5: Crystallography data table 
 
  
Dataset Terbium Native Dimer Native Tetramer
PDB code 6H6N 6H6O 6H6P
Space group P 21 21 21 P 21 21 21 P 21 21 21
Unit cell dimensions
a (Å) 48,3 48,66 47,69
b (Å) 67,93 67,87 94,55
c (Å) 73,08 74,61 115,66
Wavelength (Å) 1,6488 0,9786 0,9786
Resolution (Å) 40.29-2.11 39.55-1.70 47.28-2.5
Highest resolution bin (Å) 2.17-2.11 1.74-1.70 2.59-2.5
No. of reflections 307092 177660 137979
No. of unique reflections 13906 28017 18749
Completeness (%) 97.1 (60.7) 99.7 (96.7) 99.92 (99.94)
Rmerge 0.116 (0.709) 0.081 (1.957) 0.1602 (2.524)
I/σ (I) 12.3 (1.7) 10.7 (0.9) 9.13 (0.5)
CC1/2 0.998 (0.780) 0.999 (0.523) 0.998 (0.885)
Multiplicity 22.1 (9.3) 6.3 (6.1) 7.4 (7.7)
Refinement
Rwork 0.194 (0.189) 0.202 (0.242) 0.233 (0.224)
Rfree 0.229 (0.227) 0.248 (0.271) 0.289 (0.258)
Average B-factor (Å2)
Overall 43,05 32,65 79,12
From Wilson plot 32,35 22,83 72,21
No. of atoms
Protein 1874 1851 3585
Water 118 185 89
RMS deviations from ideal
Bond lengths (Å) 0,010 0,010 0,010
Bond angles (o) 1,07 0,98 1,27
Ramachandran outliers (%)
Residues in most favored regions (%) 98,75 99,57 98,24
Residues in allowed regions (%) 1,25 0,43 1,76
Outliers (%) 0 0 0
*Values in parentheses are for the highest resolution bin.
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Table S4 related to figure 5: Structurally characterized SCP2 proteins and their structural alignment 
with UbiJ-SCP2 
 
 
  
Protein Organism Technique Resolution PDB RMSD lipid content
Sequence 
coverage
Sequence 
Identity
Alkyl sulfatase Pseudomonas sp. DSM 6611 X-ray Diffraction 2,7 2YHE 1,563 - 67 20
Alkyl sulfatase Pseudomonas sp. DSM 6611 X-ray Diffraction 3 4AV7 2,138 - 67 20
SCP2 Human X-ray Diffraction 1,75 1IKT 2,162 Triton X-100 83 14
SCP2 Archaeoglobus fulgidus X-ray Diffraction 2,11 3BN8 2,241 - 81 11
Alkyl sulfatase Pseudomonas sp. S9 X-ray Diffraction 1,761 4NUR 2,474 - 67 17
SCP2 Aedes aegypti X-ray Diffraction 2 3BDQ 2,591 palmitic acid 90 18
SCP2 Helicoverpa armigera NMR n/a 4UEI 2,619 - 74 12
SCP2 Aedes aegypti X-ray Diffraction 1,7 2QZT 2,983 palmitic acid 90 18
SCP2 Yeast Yarrowia Lipolytica X-ray Diffraction 2,2 4JGX 3,402 palmitic acid 79 14
SCP2 Oryctolagus cuniculus X-ray Diffraction 1,8 1C44 3,483 - 68 18
SCP2 Homo sapiens NMR n/a 1QND 3,854 - 68 17
- Archaeoglobus fulgidus X-ray Diffraction 1,9 3CNU 4,084 - 90 11
SCP2 Aedes aegypti NMR n/a 2NBM 4,473 - 85 18
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Table S5 related to figure 1, 2: E. coli strains used in this study 
 
  
strain type relevant genotype source or reference
BW25113 lacI q  rrnB T14 lacZ WJ16  hsdR514 araBAD rhaBAD LD78 National BioResource Project
MG1655 Wild type ATCC
BTH101  F′, cya-99, araD139, galE15, galK16, rpsL1 (Str R ), hsdR2, mcrA1, mcrB1 Karimova et al , 1998
DY330 W3110 ∆lacU169 gal490 λCI857 ∆(cro-bioA) Hu et al , 2009
BL21 (DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS λ DE3 Merck Millipore
Keio strains Keio  collection (Baba et al , 2006)
BW25113 lacI q  rrnB T14 lacZ WJ16  hsdR514 araBAD rhaBAD LD78 Laboratory collection
BW25113 ∆ubiC As BW25113 but ∆ubiC ::Kan JW5713
BW25113 ∆ubiE As BW25113 but ∆ubiE ::Kan JW5581
BW25113 ∆ubiF As BW25113 but ∆ubiF ::Kan JW0659
BW25113 ∆ubiG As BW25113 but ∆ubiG ::Kan JW2226
BW25113 ∆blc As BW25113 but ∆blc ::Kan JW4110
Knock-out strains
MG1655 ∆ubiE As MG1655 but ∆ubiE ::Kan Hajj Chehade et al , 2013
MG1655 ∆ubiF As MG1655 but ∆ubiF ::Kan Hajj Chehade et al , 2013
MG1655∆ubiJ As MG1655 but ∆ubiJ ::Kan Aussel et al , 2014
SPA-strains
DY330 W3110 ∆lacU169 gal490 λCI857 ∆(cro-bioA) Hu et al , 2009
DY330 ubiC -SPA As DY330 but ubiC -SPA::Kan GI number 90111677
DY330 ubiF -SPA As DY330 but ubiF -SPA::Kan GI number 16128645
DY330 ubiG -SPA As DY330 but ubiG -SPA::Kan GI number 16130167
DY330 ubiH -SPA As DY330 but ubiH -SPA::Kan GI number 16130809
DY330 ubiX -SPA As DY330 but ubiX -SPA::Kan GI number 16130246
BW25113 ubiD -SPA As BW25113 but ubiD -SPA::Kan this work
BW25113 ubiI -SPA As BW25113 but ubiI -SPA::Kan this work
MG1655 ubiC -SPA MG1655 +P1/DY330 ubiC -SPA::Kan this work
MG1655 ubiD -SPA MG1655 +P1/BW25113 ubiD -SPA::Kan this work
MG1655 ubiE -SPA ubiE -SPA::Kan Loiseau et al , 2017
MG1655 ubiF -SPA MG1655 +P1/DY330 ubiF -SPA::Kan this work
MG1655 ubiG -SPA MG1655 +P1/DY330 ubiG -SPA::Kan this work
MG1655 ubiH -SPA MG1655 +P1/ DY330 ubiH -SPA::Kan this work
MG1655 ubiI -SPA MG1655 +P1/BW25113 ubiI -SPA::Kan this work
MG1655 ubiJ -SPA ubiJ -SPA::Kan Loiseau et al , 2017
MG1655 ubiK -SPA ubiK -SPA::Kan Loiseau et al , 2017
MG1655 ubiX -SPA MG1655 +P1/DY330 ubiX -SPA::Kan this work
MG1655 ubiH -SPA ∆ubiE ∆ubiE (cured with pCP20) + P1/ubiH-SPA::Kan this work
MG1655 ubiH -SPA ∆ubiF ∆ubiF  (cured with pCP20) + P1/ubiH-SPA::Kan this work
MG1655 ubiH -SPA ∆ubiG ∆ubiG  (cured with pCP20) + P1/ubiH-SPA::Kan this work
MG1655 ubiH -SPA ∆ubiJ ∆ubiJ (cured with pCP20) + P1/ubiH-SPA::Kan this work
MG1655 ubiF -SPA ∆ubiJ ∆ubiJ (cured with pCP20) + P1/ubiF-SPA::Kan this work
MG1655 ubiG -SPA ∆ubiJ ∆ubiJ (cured with pCP20) + P1/ubiG-SPA::Kan this work
MG16555 ubiI -SPA ∆ubiK ∆ubiK (cured with pCP20) + P1/ubiI-SPA::Kan this work
MG1655 ubiJ -SPA ∆ubiK ∆ubiK  (cured with pCP20) + P1/ubiJ-SPA::Kan this work
MG1655 ubiE -SPA ∆ubiC ∆ubiK (cured with pCP20) + P1/ubiE-SPA::Kan this work
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Table S6 related to figure 1: Oligonucleotides used in this study 
 
 
name category sequence
SPA-tag
5-ubiD-SPA attgacgccatctgggatgaactggctatttttaacaacggtaaaagcgccTCCATGGAAAAGAGAAG
3-ubiD-SPA catgcgctttctctgtcggatcgataaatagggcaaaacaaacgcgcatcaCATATGAATATCCTCCTTAG
5-ubiE-SPA cgactactacaatctgacggcaggggttgtggcgctgcatcgtggttataagttcTCCATGGAAAAGAGAAG
3-ubiE-SPA cctgccgtcactaaaggtttaaaaggcatttccggtctcctgtcaCATATGAATATCCTCCTTAG
5-ubiI-SPA atccgccaggcaatgggattaaacgatttgcctgaatggctgcgtTCCATGGAAAAGAGAAG
3-ubiI-SPA gatgaaagtgtgatgggtatcaaataaacaacagaggagaaatttttaCATATGAATATCCTCCTTAG
5-ubiJ-SPA gctgttgatgccctgaccaaacggctggaaaaactggaggctaaaTCCATGGAAAAGAGAAG
5-ubiJ-SPA agtgcgaatgatgaaatataggcgccgtacttcacctggcgtcatttagcctccttaCATATGAATATCCTCCTTAG
5-ubiK-SPA gagatcaaaaagcagccagatccagagactctccccccaacgctgTCCATGGAAAAGAGAAG
3-ubiK-SPA ttagaggattaattcataatttacagtgcattaaagacgaatgtttaCATATGAATATCCTCCTTAG
5-atpB SPA ttcatggttctgacgatcgtctatctgtcgatggcgtctgaagaacatTCCATGGAAAAGAGAAG
3-atpB SPA ttttccatgacagtctccagtttgtttcagttaaaacgtagtagtgttggtaaaCATATGAATATCCTCCTTAG
bacterial two-hybrid
5xbaI-ubiA GACTCTAGAGATGgagtggagtctgacgc
3xbaI-ubiA TCCGTCTAGAtcagaaatgccagtaactcattgcc
5xbaI-ubiB TCGACTCTAGAGATGACGCCAGGTGAAGTACGGCGC
3xbaI-ubiB CTTCCGTCTAGATCAGCGTGTTTTGCGCCAACCGACAAACCAGG
5xbaI-ubiC TCGACTCTAGAGATGtcacaccccgcgttaacgcaactg
3xbaI-ubiC CTTCCGTCTAGATTAgtacaacggtgacgcc
5xbaI-ubiD TCGACTCTAGAGatggacgccatgaaatataacgatttacgc
3xbaI-ubiD CTTCCGTCTAGAtcaggcgcttttaccgttgttaaaaatagccagttcatcc
5xbaI-ubiE TCGACTCTAGAGATGGTGGATAAGTCACAAGAAACGAC
3xbaI-ubiE CTTCCGTCTAGATCAGAACTTATAACCACGATGCAGCGC
5xbaI-ubiF TCGACTCTAGAGATGACAAATCAACCAACGGAAATTGC
3xbaI-ubiF CTTCCGTCTAGACTACAACCCTAACGCATATTTCAGC
5xbaI-ubiG TCGACTCTAGAGATGaatgccgaaaaatcgccggtaaaccataacgtagac
3xbaI-ubiG CTTCCGTCTAGAtcacttattctgcgtgtgcagcatatagttcac
5xbaI-ubiH GACTCTAGAGATGagcgtaatcatcgtcgg
3xbaI-ubiH TCCGTCTAGAtcaacgcgccacccaaccgagggtgcgc
5xbaI-ubiI TCGACTCTAGAGATGCAAAGTGTTGATGTAGCC
3xbaI-ubiI CTTCCGTCTAGATTAACGCAGCCATTCAGGCAAATC
5xbaI-ubiJ TCGACTCTAGAGATGCCTTTTAAACCTTTAGTGACG
3xbaI-ubiJ CTTCCGTCTAGATCATTTAGCCTCCAGTTTTTCCAGCCG
5xbaI-ubiK TCGACTCTAGAGATGATTGACCCGAAAAAAATTGAG
3xbaI-ubiK CTTCCGTCTAGATTACAGCGTTGGGGGGAGAG
5xbaI-ubiX TCGACTCTAGAGATGAAACGACTCATTGTAGGCATCAG
3xbaI-ubiX CTTCCGTCTAGATTATGCGCCCTGCCAGCG
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